Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy
company, this morning announced that it will be presenting at the upcoming
Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf
Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO
Julien Pham, MD, MPH, will lead the company’s presentation at 11:10 a.m. CT in
the Waldorf Astoria Chicago’s Sinclair Ballroom. Pham will also be available
for one-on-one meetings at the event.
To view the full press release, visit http://ibn.fm/2Ofl7
About Genprex Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex immunogene therapy for non-small cell lung cancer
(NSCLC). Genprex’s platform technologies are designed to administer cancer
fighting genes by encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
